SEC EDGARJUL 221 min read$RVTY

Gonzales Anita sold $9K of RVTY

Gonzales Anita (Vice President and CAO) sold 85 shares of REVVITY, INC. (RVTY) at $109.48 on 2026-07-20 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Gonzales Anita

Published Jul 22, 2026, 8:05 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jul 22, 2026, 8:08 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$RVTY

Neutral

high confidence

Mentioned

$RVTY

Relevance

2/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$RVTYNeutralLow

Why it matters

The disclosure provides transparency on an officer’s planned selling activity but does not introduce new company fundamentals or catalysts.

Market read

Primarily informational for insider-trading trackers; limited expected impact on trading decisions.

What to watch

The sale size is small ($9.3K) and does not include any buy/sell pattern context beyond this single transaction.

Relevance 2/10Novelty 2/10Timing: Filed on 2026-07-22 after-hours, reflecting a 2026-07-20 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Revvity, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RVTYNeutralHigh confidence

Context

Revvity CAO Anita Gonzales sold 85 shares on 2026-07-20 at $109.48/share under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a small, pre-planned open-market sale by an officer, with no accompanying guidance, operational change, or enforcement action disclosed.

Market effects

Sector

No sector read-across; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with private concerns; traders may still monitor for follow-on sales.

Key entities

Equity issuer
RVTY
Revvity, Inc., the issuer of the Form 4 insider transaction.
Insider
Anita Gonzales
Vice President and CAO who sold 85 shares under a pre-arranged 10b5-1 plan.

Read at source ← All news

SEP 1

$RVTYMed

RBC Capital initiates Revvity stock with Sector Perform rating

RBC Capital initiated coverage on Revvity Inc. (NYSE:RVTY) with a Sector Perform rating and a $135 price target. The stock trades near its 52-week high after a 31% surge over six months. RBC cited durable franchises but noted structural challenges to growth. Revvity's P/E ratio is 61, and it is considered overvalued. The company reported Q2 earnings and revenue above expectations, driven by organic growth and AI demand. Stifel raised its price target to $110 but maintained a Hold rating.

investing.com2 min

AUG 31

$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min

AUG 11

$RVTYHighAI 9/10

Revvity (RVTY) Q2 2026 Earnings Call Transcript

Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.

fool.com7 min

AUG 9

$RVTYMedAI 8/10

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

finance.yahoo.com6 min

AUG 6

$RVTYMed

Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

yahoo.com6 min

AUG 5